Bisoprolol responses (PK/PD) in hypertensive patients: A cytochrome P450 (CYP) 2D6 targeted polymorphism study

• Published in: Saudi journal of biological sciences Vol. 27; no. 10; pp. 2727 - 2732
• Main Authors: Mohammed Alkreathy, Huda, Mohammed Eid Alsayyid, Khlood, Alaama, Jumana Y., Al Ghalayini, Kamal, Karim, Shahid, Esmat, Ahmed, Damanhouri, Zoheir A.
• Format: Journal Article
• Language: English
• Published: Saudi Arabia Elsevier B.V 01.10.2020; Elsevier
• Subjects: Bisoprolol; CYP2D610; CYP2D62A; Genotyping; Hypertension; Original; Hypertension; Bisoprolol; CYP2D610; CYP2D62A; Genotyping
• ISSN: 1319-562X; 2213-7106
• DOI: 10.1016/j.sjbs.2020.06.022

Bisoprolol is an effective β1-adrenergic blocker, an inter-individual genetic variability was recorded in its response. This study aimed at investigating the association of CYP2D6*2A (rs1080985) and CYP2D6*10 (rs1065852) single-nucleotide polymorphism (SNP) with Bisoprolol response in cardiac patients attending King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia. In the study, 107 patients were enrolled. Five mL of venous blood was collected from each patient and genotyping for CYP2D6*2A and CYP2D6*10 using Vivid® CYP2D6 Green Screening Kit (Life Technologies, USA). Response to Bisoprolol was evaluated through assessment of diastolic and systolic blood pressure and by measuring Bisoprolol plasma level using triple quad mass spectrometer (TQ-MS). All patients were found to carry homozygous wild type CYP2D6*10 (GG) and none were carrying heterozygous (GA) or mutant homozygous (AA) genotype. CYP2D6*2A allele was detected in the homozygous wild type (GG) in 70 out of 107 patients, the heterozygous (GC) in 19 patients, and the homozygous mutant (CC) in 18 patients with minor allele frequency (MAF) of 25.7%. The plasma concentrations of Bisoprolol in CC carriers were significantly lower than those in GG & CC carriers by 25%, and 51%; respectively. Higher systolic and diastolic blood pressures were also observed in CC carriers than GG and CC carriers. There is a possible association of CYP2D6*2A genotype with plasma concentration of bisoprolol. This could provide a helpful tool to choose the optimum dose for bisoprolol, depending on the patient’s genotyping, in order to increase effectiveness and ameliorate its toxicity.